These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 32449213)

  • 41. Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial.
    Komori M; Ozeki A; Tanji Y; Kamiki E; Krege JH; Li LQ; Suzuki S; Shibata M; Takeshima T
    J Headache Pain; 2024 Mar; 25(1):43. PubMed ID: 38528476
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lasmiditan for the acute treatment of migraine.
    DeJulio PA; Perese JK; Schuster NM; Oswald JC
    Pain Manag; 2021 Sep; 11(5):437-449. PubMed ID: 33840206
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of binding, functional activity, and contractile responses of the selective 5-HT
    Rubio-Beltrán E; Labastida-Ramírez A; Haanes KA; van den Bogaerdt A; Bogers AJJC; Zanelli E; Meeus L; Danser AHJ; Gralinski MR; Senese PB; Johnson KW; Kovalchin J; Villalón CM; MaassenVanDenBrink A
    Br J Pharmacol; 2019 Dec; 176(24):4681-4695. PubMed ID: 31418454
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lasmiditan for acute treatment of migraine.
    Parikh S
    Drugs Today (Barc); 2021 Feb; 57(2):89-100. PubMed ID: 33656015
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rational Use of Lasmiditan for Acute Migraine Treatment in Adults: A Narrative Review.
    Ferrari A; Rustichelli C
    Clin Ther; 2021 Apr; 43(4):654-670. PubMed ID: 33608115
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study.
    Ashina M; Reuter U; Smith T; Krikke-Workel J; Klise SR; Bragg S; Doty EG; Dowsett SA; Lin Q; Krege JH
    Cephalalgia; 2021 Mar; 41(3):294-304. PubMed ID: 33541117
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New Migraine Medication.
    Aschenbrenner DS
    Am J Nurs; 2020 Feb; 120(2):20-21. PubMed ID: 31977411
    [No Abstract]   [Full Text] [Related]  

  • 48. Efficacy and tolerability of 100 mg of lasmiditan for migraine: A multi-center, prospective observational real-world study in Japan.
    Ishii R; Ishizuchi K; Watanabe N; Fukazawa R; Trivedi M; Nakahara J; Takizawa T
    Cephalalgia; 2024 Jun; 44(6):3331024241258695. PubMed ID: 38859749
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine.
    Tsai M; Nery ESM; Kerr L; Khanna R; Komori M; Dennehy EB; Wilbraham D; Winner P
    Clin Pharmacokinet; 2021 Jun; 60(6):819-828. PubMed ID: 33565026
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan--a randomised proof-of-concept trial.
    Ferrari MD; Färkkilä M; Reuter U; Pilgrim A; Davis C; Krauss M; Diener HC;
    Cephalalgia; 2010 Oct; 30(10):1170-8. PubMed ID: 20855362
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy.
    Anderson CC; VanderPluym JH
    Drug Des Devel Ther; 2023; 17():1979-1993. PubMed ID: 37426628
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Next-day residual effects of gabapentin, diphenhydramine, and triazolam on simulated driving performance in healthy volunteers: a phase 3, randomized, double-blind, placebo-controlled, crossover trial.
    Kay GG; Schwartz HI; Wingertzahn MA; Jayawardena S; Rosenberg RP
    Hum Psychopharmacol; 2016 May; 31(3):217-26. PubMed ID: 27018419
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The selective 5-HT
    Vila-Pueyo M; Page K; Murdock PR; Loraine HJ; Woodrooffe AJ; Johnson KW; Goadsby PJ; Holland PR
    Br J Pharmacol; 2022 Feb; 179(3):358-370. PubMed ID: 34600443
    [TBL] [Abstract][Full Text] [Related]  

  • 54. On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers.
    Vermeeren A; Jongen S; Murphy P; Moline M; Filippov G; Pinner K; Perdomo C; Landry I; Majid O; Van Oers ACM; Van Leeuwen CJ; Ramaekers JG; Vuurman EFPM
    Sleep; 2019 Apr; 42(4):. PubMed ID: 30597112
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study.
    Kuca B; Silberstein SD; Wietecha L; Berg PH; Dozier G; Lipton RB;
    Neurology; 2018 Dec; 91(24):e2222-e2232. PubMed ID: 30446595
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety profile of lasmiditan in patients with migraine in an Asian population.
    Hirata K; Matsumori Y; Tanji Y; Khanna R; Ozeki A; Komori M
    Expert Opin Drug Saf; 2023 Jan; 22(1):91-101. PubMed ID: 35736027
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial.
    Marcus R; Goadsby PJ; Dodick D; Stock D; Manos G; Fischer TZ
    Cephalalgia; 2014 Feb; 34(2):114-25. PubMed ID: 23965396
    [TBL] [Abstract][Full Text] [Related]  

  • 58. On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly.
    Vermeeren A; Vets E; Vuurman EF; Van Oers AC; Jongen S; Laethem T; Heirman I; Bautmans A; Palcza J; Li X; Troyer MD; Wrishko R; McCrea J; Sun H
    Psychopharmacology (Berl); 2016 Sep; 233(18):3341-51. PubMed ID: 27424295
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials.
    Loo LS; Ailani J; Schim J; Baygani S; Hundemer HP; Port M; Krege JH
    J Headache Pain; 2019 Jul; 20(1):84. PubMed ID: 31340760
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance.
    Verster JC; Volkerts ER; Schreuder AH; Eijken EJ; van Heuckelum JH; Veldhuijzen DS; Verbaten MN; Paty I; Darwish M; Danjou P; Patat A
    J Clin Psychopharmacol; 2002 Dec; 22(6):576-83. PubMed ID: 12454557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.